Jevtana is relevant as a therapeutic option used in the sequencing of chemotherapy for patients with advanced prostate cancer. This medicine is used when the cancer has progressed after having already received another taxane-based drug.

---

What Jevtana Treats: Conditions and Benefits

This medicine is applied in clinical settings where a subsequent therapy is considered appropriate, specifically for patients whose disease has progressed, requiring ongoing management of their condition. It is commonly used for metastatic castration-resistant prostate cancer (mCRPC) when the condition has continued to advance after a docetaxel-containing treatment regimen.

The use of this medicine is considered relevant for providing supportive relief during the course of the advanced condition. This helps maintain a sense of stability when previous systemic control has been affected. Jevtana may also be relevant for addressing key indicators of disease activity, such as rising Prostate-Specific Antigen (PSA) levels, which is associated with management of the overall symptom load.

Quick Fact: Relief for Disease Progression

The therapy is used when previous systemic treatments are no longer effective, providing a treatment option that supports the management of the advanced, spreading condition.

Who Can and Cannot Use Jevtana?

Eligibility for Jevtana (cabazitaxel) is strictly defined by regulatory authorities and depends on a patient's medical status and treatment history.

Use is permitted for:

• Adult male patients with metastatic castration-resistant prostate cancer.
• Patients whose disease has progressed during or after prior docetaxel-containing treatment.

---

Use is strictly contraindicated (must not be used) if a patient has:

• Low Neutrophil Count: Pre-treatment neutrophil counts of le 1,500 cells/mm^3.
• Severe Hepatic Impairment: Liver function is severely compromised (Total Bilirubin > 3 imes Upper Limit of Normal, ULN).
• Severe Hypersensitivity: A history of severe allergic reactions to cabazitaxel or to other products formulated with polysorbate 80.

Patients with moderate hepatic impairment may be eligible only with a dose reduction, and its use is not generally recommended. Additionally, male patients must be advised to use effective contraception during treatment and for a specified time afterward, as the medicine can cause fetal harm.

Jevtana Interactions with other medicines and products

Official regulatory information documents that Cabazitaxel interacts with several classes of medicinal products and substances through both metabolic pathways and increased risks.

Interaction Type	Interacting Substances/Classes
Exposure Modification (CYP3A)	Strong CYP3A Inhibitors (e.g., ketoconazole, clarithromycin) and Strong CYP3A Inducers (e.g., rifampicin).
Risk Reinforcement (Pharmacodynamic)	NSAIDs, anti-platelet therapy, and anti-coagulants (increased risk of serious gastrointestinal complications).
Formal Contraindication (Substance-Related)	Products formulated with Polysorbate 80 (for hypersensitive patients) and Live Attenuated Vaccines.

The labels specify that co-administration with strong CYP3A inhibitors or inducers must be avoided due to the potential to either significantly increase or reduce Cabazitaxel plasma exposure. If co-administration with a strong CYP3A inhibitor is required, a modification of the Cabazitaxel dose is formally documented as necessary. The mandatory premedication regimen, which includes a corticosteroid and an H2 antagonist, must be administered intravenously at least 30 minutes prior to the Cabazitaxel infusion. Furthermore, dietary substances like Grapefruit and Grapefruit juice must be avoided due to their potential to increase drug levels. Hepatic impairment and advanced age (ge 65 years) are documented population-specific conditions that alter drug disposition and risk profile, requiring specific consideration.

Jevtana is a semisynthetic taxoid and a microtubule inhibitor. Its mechanism of action involves the intracellular structure of alpha- and beta-tubulin subunits, which are the main components of microtubules. Cabazitaxel binds specifically to beta-tubulin, promoting the assembly of these subunits into microtubules while simultaneously inhibiting the critical process of microtubule disassembly (depolymerization). This dual action stabilizes the entire microtubule network.

The resulting network stabilization prevents the normal dynamic reorganization required for cellular functions, particularly during mitosis. By disrupting the spindle dynamics, cabazitaxel causes the cell to become arrested in the G2/M phase of the cell cycle. This sustained mitotic arrest initiates the final downstream cascade of programmed cell death, known as apoptosis.

Furthermore, cabazitaxel exhibits low affinity for the P-glycoprotein (P-gp) efflux pump, a membrane transporter that can actively remove other taxanes from cells, allowing the drug to maintain an intracellular concentration capable of modifying microtubule structure.

How Jevtana is Used: Administration and Preparation

Jevtana (cabazitaxel) is an anticancer agent governed by strict procedural rules for its preparation and delivery.

---

Administration and Schedule

Parameter	Description
Route of Administration	Exclusively via Intravenous (IV) infusion over a fixed one-hour period.
Dosing Schedule	Administered once every three weeks (Q3W), in combination with oral prednisone or prednisolone 10 mg daily.
Standard Dosing	The dose is calculated based on Body Surface Area (BSA). The typical recommended starting dose is 20 mg/m^2, though 25 mg/m^2 may be used in select patient populations.
Hepatic Adjustment	Dose adjustments are required for impaired liver function: for mild hepatic impairment, the dose is 20 mg/m^2, and for moderate hepatic impairment, the maximum dose is 15 mg/m^2.

Preparation and Procedural Steps

The preparation of Jevtana must be carried out in a specialized clinical setting and involves several mandatory procedural steps:

• Dilution Process: The concentrate requires a two-step dilution process before the final solution is ready for IV infusion.
• Premedication: A specific IV premedication regimen (including an antihistamine, corticosteroid, and H2 antagonist) must be given at least 30 minutes prior to each infusion.
• Equipment Restriction: The use of PVC infusion containers and polyurethane infusion sets is prohibited for the preparation and administration of the final solution.
• Filtration: An in-line 0.22 micrometer filter must be used during the infusion to ensure proper administration.

These procedural requirements define the complete, standardized use protocol, ensuring controlled delivery during the Q3W cycle in a specialized care environment.

Research Evidence: Overview of Studies for Jevtana

This section provides a factual summary of the formal research and clinical trials that define the approved study of Jevtana (cabazitaxel), focusing on the study designs, populations, and the major outcomes was studied for, as reported by regulatory and authoritative scientific sources. The research provides context but not individual predictions.

Evidence for Use in Progressive Prostate Cancer After Docetaxel

The initial evidence supporting the study of Jevtana was evaluated in a large-scale, international Phase III randomized study known as the TROPIC trial. This research was studied for its potential role as a subsequent treatment option for metastatic castration-resistant prostate cancer (mCRPC) that had progressed following a prior docetaxel-containing treatment regimen.

Researchers examined the study agent compared to a historical chemotherapy drug, Mitoxantrone. The primary outcome the studies monitored was Overall Survival (OS). Studies reported patterns in Overall Survival that were observed in the group receiving the study agent when compared to the Mitoxantrone group. Research reported differences in the proportion of patients who remained alive after two years between the study agent group and the comparator group.

Evidence for Use After Both Docetaxel and New Hormonal Agents

A later Phase III randomized study, known as the CARD trial, research examined the study agent in patients who had experienced disease progression after receiving both a docetaxel-containing therapy and an androgen receptor (AR)-targeted agent. The primary outcome studies monitored was Radiographic Progression-Free Survival (rPFS). Findings describe patterns observed in the studies where median rPFS and OS measurements were higher for the study agent group when compared to the alternative AR-targeted agent group.

What Remains Uncertain: Evidence Gaps and Limitations

A key limitation noted for the initial TROPIC trial is that the comparator was Mitoxantrone, meaning comparative evidence is lacking against many of the current standard therapies. Furthermore, patients with severe hepatic impairment were typically excluded from the large randomized trials. Therefore, data for certain groups remain insufficient, and research is insufficient to draw conclusions for this population. Long-term effects are not fully established beyond the observation periods of the key trials.

Common questions about Jevtana (FAQ)

Q: Why do patients need to take the steroid prednisone along with Jevtana?

Official product information states that this medicine is indicated for use only in combination with oral prednisone (or prednisolone). This steroid is typically taken daily throughout the entire treatment period. This combination is a mandated part of the approved treatment regimen.

Q: What is peripheral neuropathy, and is it a temporary or long-lasting side effect?

Peripheral neuropathy is a known adverse effect that involves damage to the nerves, which may cause symptoms like numbness or tingling. Regulatory documentation describes management strategies for this condition. If a patient develops persistent or severe peripheral neuropathy, the medicine's dose may need to be reduced or discontinued.

Q: Can patients with pre-existing kidney problems still be treated with Jevtana?

Official regulatory protocols state that no dose adjustment is generally needed for most patients with existing reduced kidney function. However, official information indicates caution is needed, and close monitoring for toxicity is specified for patients with severe kidney problems.

Q: Is a low platelet count a common risk that leads to bruising or bleeding?

Yes, a low blood platelet count, also known as thrombocytopenia, is reported as a common adverse reaction. Since platelets help the blood clot, a reduction in their number may increase the risk of bruising or bleeding.

Q: What does it mean for prostate cancer to be 'castration-resistant'?

This medicine is approved for metastatic castration-resistant prostate cancer (mCRPC). This term describes prostate cancer that continues to progress despite prior hormone-lowering treatment.

Q: What are the possible signs of an infection while receiving this medicine?

Because this medicine can cause a dangerously low white blood cell count (neutropenia), regulatory patient information describes signs of infection to be aware of. These signs can include having a fever, developing a cough, experiencing muscle aches, or a burning sensation during urination.

Q: Does Jevtana commonly cause hair loss or hair thinning?

Yes, regulatory data indicates that hair loss, known as alopecia, is reported as a very common side effect of this medicine.

Q: Can Jevtana cause a change in my sense of taste?

Yes, a change in your sense of taste, medically termed dysgeusia, is reported in official product information as a very common side effect.

Q: Why do some patients need an injection (G-CSF) to help with their white blood cell count?

G-CSF (Granulocyte-Colony Stimulating Factor) is sometimes recommended as a preventative measure for patients with certain high-risk factors. This injection is given to help boost the white blood cell count and reduce the risk of serious complications like febrile neutropenia.

Q: Is blood in the urine or painful urination a common side effect of Jevtana?

Official information indicates that blood in the urine (hematuria) is reported as a very common side effect. Additionally, painful or difficult urination (dysuria) is classified as a common side effect.

Q: Does Jevtana work on bone metastases in prostate cancer?

The medicine is approved for the systemic treatment of metastatic castration-resistant prostate cancer. This systemic approach addresses the overall spread of cancer, which includes disease that may be present in the bone.

Q: What are the signs of a lung or breathing problem that can happen with Jevtana?

Shortness of breath (dyspnea) and cough are listed as common side effects. Regulatory documents also note that serious lung problems, such as interstitial pneumonia, have been reported.

Q: Is it necessary to have blood work done before every Jevtana treatment cycle?

Yes, frequent blood cell counts are mandatory, as specified in the administration guidelines. This monitoring is necessary because treatment is contraindicated if the neutrophil count is below the required threshold.

Q: What kind of vision changes have been reported with the use of Jevtana?

Official safety data indicates that blurred vision has been reported as a less common side effect.

Q: Does previous radiation therapy to the pelvis increase the risk of certain side effects with Jevtana?

Yes, official safety information states that patients who previously received radiation therapy to the pelvic area are specifically identified for monitoring. This is to check for signs of cystitis, which is inflammation of the bladder.

Q: What measures are usually taken to prevent or manage severe gastrointestinal issues?

Doctors are advised to treat patients with supportive care, including anti-emetics to prevent vomiting and anti-diarrheals as needed. Adequate rehydration is also a documented measure used to manage severe gastrointestinal side effects.

How to Store and Dispose of Jevtana

The storage and disposal of Jevtana (cabazitaxel) must strictly adhere to regulatory requirements for a cytotoxic agent.

---

Official Storage Conditions

The unopened concentrate and solvent vials must be stored in the original outer carton to protect them from light, at a temperature below 25°C (77°F). The vials must not be refrigerated or frozen.

Stability After Preparation	Condition
Reconstituted Concentrate	Must be further diluted within 30 minutes
Final Infusion Solution	Stable for 8 hours at room temperature or 24 hours when refrigerated (2°C to 8°C)

Preparation and administration must not use PVC infusion containers or polyurethane infusion sets. The final solution must be discarded if any crystallization is visible.

---

Disposal Requirements

Jevtana must be kept out of the sight and reach of children.

As a cytotoxic product, unused medicine and waste material must not be thrown away via wastewater or household waste. Disposal must follow the special local requirements for cytotoxic waste.